We are live on ! Find out more
CSCI

COSCIENS Biopharma

Delisted

CSCI was delisted on the 3rd of September, 2025.

15 hedge funds and large institutions have $996K invested in COSCIENS Biopharma in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more capital inflows, than outflows

Capital inflows: $286K | Capital outflows: $93.3K

0.64% more ownership

Funds ownership: 2.47% → 3.11% (+0.64%)

6% less funds holding

Funds holding: 16 → 15 (-1)

20% less call options, than puts

Call options by funds: $43K | Put options by funds: $54K

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
6
Closed
4
Calls
$43​K
Puts
$54​K
Net Calls
-⁠$11​K
Net Calls Change
+$1​K

CSCI Hedge Fund Activity: Q2 2018 in Review

15 of the 4,387 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma (CSCI) for Q2 2018, worth a combined $996K — up 68% from $591K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CSCI and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $200K. The largest seller was Susquehanna International Group, cutting an estimated $55.9K.

  • 15 institutional investors held COSCIENS Biopharma (CSCI) as of Q2 2018, down from 16 in Q1 2018.
  • Funds reported $996K of COSCIENS Biopharma stock for Q2 2018, up 68% quarter-over-quarter.
  • 3 funds opened new COSCIENS Biopharma positions in Q2 2018 and 4 closed out, a net change of -1 holder.
  • The largest COSCIENS Biopharma buyer in Q2 2018 was Morgan Stanley, an estimated $200K added.
  • The largest COSCIENS Biopharma seller in Q2 2018 was Susquehanna International Group, an estimated $55.9K sold.

Based on aggregated 13F filings for Q2 2018.